Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer | Zendy

Jinbiao Zhan | Zendy; Qian Ding | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer

Author(s) -

Jinbiao Zhan,

Qian Ding

Publication year - 2013

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s41910

Subject(s) - carboplatin , medicine , lung cancer , oncology , cisplatin , combination therapy , clinical trial , chemotherapy , combination chemotherapy

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer characterized by early metastasis and high mortality. In recent years, monotherapy and combination therapy of amrubicin with cisplatin or carboplatin has been actively studied and shown promise for the treatment of extensive disease SCLC (ED-SCLC). In this article, we summarize clinical trials of both monotherapy and combination therapy with amrubicin conducted in Japan, the USA, and the European Union. The results suggest that the clinical outcome of amrubicin therapy may be associated with genetic variations in patients. Further study of combination regimens in patients of different ethnicities is warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research